S33138 [N-[4-[2-[(3 aS,9 bR)-8-cyano-1,3 a,4,9 b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors
Open Access
- 1 February 2008
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 324 (2) , 587-599
- https://doi.org/10.1124/jpet.107.126706
Abstract
The novel, potential antipsychotic, S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide), displayed ∼25-fold higher affinity at human (h) dopamine D3 versus hD2L (long isoform) and hD2S (short isoform) receptors (pKi values, 8.7, 7.1, and 7.3, respectively). Conversely, haloperidol, clozapine, olanzapine, and risperidone displayed similar affinities for hD3, hD2L, and hD2S sites. In guanosine-5′-O-(3-[35S]thio)-triphosphate ([35S]-GTPγS) filtration assays, S33138 showed potent, pure, and competitive antagonist properties at hD3 receptors, displaying pKB and pA2 values of 8.9 and 8.7, respectively. Higher concentrations were required to block hD2L and hD2S receptors. Preferential antagonist properties of S33138 at hD3 versus hD2L receptors were underpinned in antibody capture/scintillation proximity assays (SPAs) of Gαi3 recruitment and in measures of extracellular-regulated kinase phosphorylation. In addition, in cells cotransfected with hD3 and hD2L receptors that assemble into heterodimers, S33138 blocked (pKB, 8.5) the inhibitory influence of quinpirole upon forskolin-stimulated cAMP formation. S33138 had low affinity for hD4 receptors (1 receptors (Gαs/SPA, pKB, 6.3) and hD5 sites (adenylyl cyclase, 6.5). Modest antagonist properties were also seen at human serotonin (5-HT)2A receptors (Gαq/SPA, pKB, 6.8, and inositol formation, 6.9) and at 5-HT7 receptors (adenylyl cyclase, pKB, 7.1). In addition, S33138 antagonized hα2C adrenoceptors ([35S]GTPγS, 7.2; Gαi3/SPA, 6.9; Gαo/SPA, 7.3, and extracellular-regulated-kinase, 7.1) but not hα2A or hα2B adrenoceptors (1-adrenoceptor, muscarinic, and histamine receptor. In conclusion, S33138 possesses a distinctive receptor-binding profile and behaves, in contrast to clinically available antipsychotics, as a preferential antagonist at hD3 versus hD2 receptors.This publication has 77 references indexed in Scilit:
- The structural evolution of dopamine D3 receptor ligands: Structure–activity relationships and selected neuropharmacological aspectsPharmacology & Therapeutics, 2006
- Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial AgonistThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studiesEuropean Psychiatry, 2005
- Comparative Studies of Molecular Mechanisms of Dopamine D2 and D3 Receptors for the Activation of Extracellular Signal-regulated KinaseJournal of Biological Chemistry, 2004
- Signaling Mechanisms of the D3Dopamine ReceptorJournal of Receptors and Signal Transduction, 2004
- Differential Activation of Gq/11 and Gi3 Proteins at 5-Hydroxytryptamine2C Receptors Revealed by Antibody Capture Assays: Influence of Receptor Reserve and Relationship to Agonist-Directed TraffickingMolecular Pharmacology, 2002
- Ligand modulation of [35S]GTPγS binding at human α2A, α2B and α2C adrenoceptorsCellular Signalling, 2002
- Inverse Agonist Properties of Dopaminergic Antagonists at the D1ADopamine Receptor: Uncoupling of the D1ADopamine Receptor from GsProteinMolecular Pharmacology, 1999
- Human Dopamine D3Receptors Mediate Mitogen-Activated Protein Kinase Activation Via a Phosphatidylinositol 3-Kinase and an Atypical Protein Kinase C-Dependent MechanismMolecular Pharmacology, 1999
- Adverse Effects of Antipsychotic AgentsDrugs, 1996